Company Overview and News

 
Henderson Land looks to farmland conversion, ageing buildings to stoke development pipeline

2018-06-02 scmp
Henderson Land Development will look to a combination of sites sold at government tender and private land acquisitions to help replenish its land bank at a time of soaring property values in Hong Kong.
HDVTY HDVTF 0097 0012

 
Henderson to buy Japanese retailer FamilyMart’s Hong Kong stores for US$38 million

2018-05-25 scmp
Property developer Henderson Land plans to acquire the Hong Kong unit of FamilyMart UNY, Japan’s second-largest convenience store chain, for HK$300 million (US$38 million) through its investment subsidiary, it announced on Thursday.
HDVTY HDVTF 0097 0012

12
Henderson Land’s underlying profit rises 38 per cent, beats estimates

2018-03-21 scmp
Lee Shau-kee’s property company reveals it has majority stakes in 51 old tenement buildings that could be redeveloped
HDVTY HDVTF 0097 MS 0012

4
Hong Kong sees massive wealth transfer from tycoons to heirs

2018-03-20 bworldonline
THE RETIREMENT of Hong Kong billionaire Li Ka-shing marks another milestone in a vast wealth transfer now underway from a scrappy generation of Chinese empire builders to their heirs.
HDVTY CJEWY WARFY SHGKY 0097 0086 CKHUY 0012 SUHJF SUHJY 0017 0016 SHGKF CJEWF WARFF CKHUF UBS HDVTF ULSGF

4
Hong Kong sees massive wealth transfer from tycoons to heirs

2018-03-20 themalaymailonline
Li Ka-shing listens to his son Victor Li, Co-Managing Director and Deputy Chairman of CK Hutchison Holdings Limited, during a news conference in Hong Kong March 16, 2018. — Reuters picHONG KONG, March 20 — The retirement of Hong Kong billionaire Li Ka-shing marks another milestone in a vast wealth transfer now underway from a scrappy generation of Chinese empire builders to their heirs.
HDVTY CJEWY WARFY SHGKY 0097 0086 CKHUY 0012 SUHJF SUHJY 0017 0016 SHGKF CJEWF WARFF CKHUF UBS HDVTF ULSGF

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...